TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
Maravai LifeSciences Holdings, Inc. - Class A common stock (MRVI)
Company Research
Source: Business Wire
cGMP Facility Streamlines Clinical & Commercial mRNA Drug Substance Development;Built by mRNA & Industry Experts to Meet Demand for mRNA-based Medicine SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility. The 32,000-square-foot facility was specifically designed for mRNA manufacturing to support late-phase drug developers from Phase 2 to commercialization via TriLink’s robust mRNA manufacturing capabilities. The milestone opening is expected to help advance the field of mRNA-based medicine as developers flock to leverage the promising modality for a growing list of indications.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418722567/en/TriLink BioTechnologies® Cuts Ribbon on New San Diego Facility for Late Phase mRNA Drug Substa
Show less
Read more
Impact Snapshot
Event Time:
MRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRVI alerts
High impacting Maravai LifeSciences Holdings, Inc. - Class A common stock news events
Weekly update
A roundup of the hottest topics
MRVI
News
- TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology [Yahoo! Finance]Yahoo! Finance
- TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping TechnologyBusiness Wire
- TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production [Yahoo! Finance]Yahoo! Finance
- Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024GlobeNewswire
- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $15.00 price target on the stock.MarketBeat
MRVI
Earnings
- 2/22/24 - Beat
MRVI
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEF
- 4/16/24 - Form 4
- MRVI's page on the SEC website